Efficacy and safety of empagliflozin in type 2 diabetes mellitus saudi patients as add-on to antidiabetic therapy: a prospective, open-label, observational study

HIGHLIGHTS

• who: Fahad M. Althobaiti et al. from the Department of Pharmacology and, Faculty of Medicine, Al-Qura University (UQU), Makkah, Arabia have published the research work: Efficacy and Safety of Empagliflozin in Type 2 Diabetes Mellitus Saudi Patients as Add-On to Antidiabetic Therapy: A Prospective, Open-Label, Observational Study, in the Journal: (JOURNAL)
• what: This study aimed to assess the efficacy and safety of EMPA in patients (n = with T2DM. This study demonstrated an improvement in kidney function, reduced UCAR, and improved eGFR.
• future: Research is needed to investigate the adverse effects . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.